Suguru Saho

Suguru Saho

Auto-generated profile, based on publicly available information

Suguru Saho

Department of Medical Joint Materials, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Kagoshima, 890-8520, Japan

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2026 in Osteoarthritis and Cartilage Open
Verified
Journal Article
Open access
TITomohiro Iuchi
Tomohiro Iuchi
KSKento Shimanoe
Kento Shimanoe
TITakayuki Ide
Takayuki Ide
STSeiya Takada
Seiya Takada
SSSuguru Saho
Suguru Saho
NTNoboru Taniguchi
Noboru Taniguchi
To characterize bone morphogenetic protein (BMP) signaling in cuff tear arthropathy (CTA) using a modified rat model (mCTA) and determine whether inhibition of DMH1-sensitive BMP type I receptor signaling attenuates CTA pathology. The rat mCTA model was generated by resection of the supraspinatus and infraspinatus tendons, the superior joint capsule, and the long head of the biceps tendon. Single-cell RNA sequencing (scRNA-seq) was performed to characterize BMP ligand expression in the humeral head. BMP-2, BMP-7, and phosphorylated Smad1/5 (p-Smad1/5) were evaluated by immunohistochemistry, and Id1 expression was assessed by RT-qPCR. Synovial macrophage subsets were assessed by immunostaining. Rats received daily intraperitoneal DMH1 (10 mg/kg) or vehicle for 4 weeks. Histological scores, bone volume, osteoclast number, inflammatory cytokines, catabolic enzymes, and macrophage markers were quantified. scRNA-seq revealed expression of BMP ligands. In mCTA cartilage, BMP-2 and BMP-7 expression, p-Smad1/5 signaling, and hypertrophic markers (Runx2, Col10a1) were upregulated. DMH1 suppressed Smad1/5 activation, reduced inflammatory and catabolic gene expression, and attenuated cartilage degeneration. In subchondral bone, BMP signaling was associated with increased osteoclast numbers, RANKL/OPG imbalance, and reduced bone volume, all of which were improved by DMH1 treatment. In the synovium, BMP signaling and inflammatory mediators were elevated with increased macrophage numbers; DMH1 reduced inflammatory mediators and M1 macrophage numbers. BMP-Smad1/5 signaling is activated in multiple joint tissues in mCTA and is associated with cartilage degeneration, subchondral bone resorption, and synovial inflammation. These findings suggest that BMP-Smad1/5 signaling may contribute to the pathological changes observed in mCTA.

2 October 2026 in Bone & Joint Research
Verified
Journal Article
Open access
PDF file
TITakayuki Ide
Takayuki Ide
YMYusuke Masuda
Yusuke Masuda
KSKento Shimanoe
Kento Shimanoe
SSSuguru Saho
Suguru Saho
STSeiya Takada
Seiya Takada
NTNoboru Taniguchi
Noboru Taniguchi
Aims: Enhanced osteoclast activity in subchondral bone is implicated in osteoarthritis (OA) progression, but the contribution of osteoclasts versus synovial inflammation in cuff tear arthropathy (CTA) remains unclear. This study investigated whether inhibition of osteoclasts using an anti-receptor activator of nuclear factor κB ligand (RANKL) antibody can suppress joint degeneration in a mouse CTA model without affecting synovial inflammation. Methods: A modified CTA (mCTA) model was established in mice by resecting the supraspinatus and infraspinatus tendons, the superior joint capsule, and the long head of the biceps tendon in the right shoulder of C57BL/6J mice. Mice were assigned to four groups: sham or mCTA, each treated with phosphate-buffered saline or anti-RANKL antibody (5 mg/kg subcutaneously every two weeks). Four weeks post-surgery, histological analyses of the humeral head were performed using the Murine Shoulder Arthritis Score (MSAS), immunohistochemistry for osteoclasts, osteoblasts, RANKL/osteoprotegerin (OPG), inflammatory cytokines, and catabolic enzymes, and quantification of synovial M1 macrophages. Subchondral bone volume (BV) was assessed via the bone volume/tissue volume ratio. Results: The mouse mCTA model reproduced clinically relevant CTA phenotypes, including cartilage degeneration, subchondral bone loss, and joint surface collapse, within four weeks. RANKL expression and osteoclast surface increased in the superior and middle zones, while osteoblasts decreased. Synovial RANKL expression was low and unchanged after mCTA surgery. Anti-RANKL antibody administration significantly suppressed osteoclast surface and preserved subchondral BV, leading to attenuation of cartilage degeneration and reduced expression of inflammatory cytokines and catabolic enzymes in cartilage and subchondral bone. The synovitis score, synovial M1 macrophages, and inflammatory factors were unaffected, indicating that suppression of osteoclasts was sufficient to mitigate joint degeneration. Conclusion: Inhibition of subchondral osteoclasts via anti-RANKL antibody reduces CTA-associated cartilage and bone degeneration without altering synovitis. These findings suggest that targeting osteoclasts may represent a promising disease-modifying strategy for CTA, and targeting RANKL with denosumab may prevent or slow shoulder OA progression. Cite this article: Bone Joint Res 2026;15(10):1183–1195.